OneLab

Name

OneLab

Legal name

LatentSpace Therapeutics, LLC

Website

https://onelaboratory.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

AI-Driven Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• AI drug discovery
• Computational drug design
• In-silico pharmacology
• Preclinical therapeutics
• Machine learning biotech

Headquarters

HQ city

Lisbon

HQ country

Portugal

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

OneLab operates as an AI-driven drug discovery company that uses its proprietary ✦PULSAR✦ platform to design best-in-class medicines from inception for challenging cancers and complex diseases. The platform integrates in-silico retrosynthesis, toxicity, and efficacy assessments to identify and generate novel chemical entities with large therapeutic windows, accelerating the selection of preclinical development candidates and reducing time and cost compared with traditional drug development.

Product overview

LatentSpace Therapeutics operates as a single unified AI-driven drug discovery platform built around PULSAR, their core drug design technology. PULSAR integrates in-silico testing capabilities including retrosynthesis, toxicity, and efficacy assessments to identify promising therapeutic candidates and accelerate the selection of development candidates.

Differentiator

Problem solved

Functional benefit

Products and services

• ✦PULSAR✦ Drug Design Platform An AI-driven drug design platform that analyzes extensive pharmacological data to identify patterns in drug efficacy and safety, integrates in-silico retrosynthesis, toxicity, and efficacy assessments, and rapidly generates novel chemical entities with large therapeutic windows; intended for use by the company's own drug discovery pipeline targeting challenging cancers and complex diseases.

Quantifiable outcome

• Significantly reduced time and cost associated with traditional drug development through AI-driven candidate selection

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature1 record

Recent moves4 records

Expansion highlights4 records

Direct peers

• XtalPi: AI-driven drug discovery company combining physics-based modeling, ML, and robotics to design and prioritize candidates — comparable end-to-end AI drug discovery approach.
• BenevolentAI: AI-driven drug discovery company using ML on biomedical knowledge graphs to identify novel targets and compounds — comparable in using AI to design new chemical entities for complex diseases.
• Atomwise: AI-driven small molecule drug design company using structure-based ML to identify novel chemical entities — comparable to PULSAR's NCE-generation and cellular potency prediction capabilities.
• Schrödinger: Computational chemistry and physics-based drug design platform with software and internal pipeline — directly comparable in its AI/ML-led approach to designing new chemical entities with favorable potency and safety profiles.
• Isomorphic Labs: Alphabet-backed AI drug discovery company building an end-to-end computational drug design engine — comparable to PULSAR as an integrated, ML-native drug discovery platform with therapeutic ambition.
• Genesis Therapeutics: AI-native biotech combining graph neural networks and molecular simulations to design new chemical entities — directly comparable in its use of generative AI for potency-and-property-optimized small molecule design.
• Insitro: AI/ML-enabled drug discovery platform combining ML with high-throughput biology and real-world patient data to design therapeutics — directly comparable to PULSAR's use of ML and real-world pharmacological evidence.
• Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with ML to generate and advance therapeutic candidates — directly comparable business model and value proposition to LatentSpace's PULSAR platform.

Emerging players

• Iambic Therapeutics: Early-stage AI-native drug discovery platform using ML for novel chemical entity design — comparable in stage and AI-native philosophy, though with a more disclosed pipeline emphasis.
• Iambic (formerly Inception/AION): AI-native biotech applying ML models to design differentiated therapeutics from inception — closely comparable in "design best-in-class from inception" positioning to LatentSpace's PULSAR thesis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks3 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OneLab